Advertisement

Topics

Insmed's lung drug meets main goal in key study, shares soar

10:58 EDT 5 Sep 2017 | Topix

Insmed Inc said its drug for the treatment of a rare lung disorder met the main goal in a key study, sending its shares soaring in premarket trading on Tuesday. The drug, Alis, was used for the treatment of resistant nontuberculous mycobacterial lung infections in a late-stage study that involved 336 adult patients.

Original Article: Insmed's lung drug meets main goal in key study, shares soar

NEXT ARTICLE

More From BioPortfolio on "Insmed's lung drug meets main goal in key study, shares soar"

Quick Search
Advertisement